Preliminary study results highlight potential of Cassia fistula as a digestive aid

Image | adobe.stock/yotrakbutda

In a March 10, 2025, press release, Logical Square announced results from an open-label clinical study on the ingredient CaFi, comparing its effects to supplementation with senna-based products. According to logic square, use of senna (Cassia angustifolia) is considered unsuitable for long-term use, or use by children and older adults. Based on Cassia fistula (golden shower tree), CaFi has a lower sennoside content, high mucilage content, and a sweet taste, which can allow for more accessible, long-term, safer use. The completed study is intended to soon be published in a journal.

“We believe we have a truly relevant, unique product for the gut health market, one that will impact the lives of millions who suffer from digestive issues,” stated Sanjay Tamoli, PhD, technical partner, Logical Square, in the press release. “Senna is a well-established gut health ingredient but current offerings come with side effects that turn people off from its use. Our product builds on senna’s history of use but is a better, healthier version that will be a gamechanger for people who want a product that works but not at the expense of their quality of life.”

In the comparison study, 67 participants ages 18–67 with irregular bowel habits or constipation received either 1 CaFi Tablet (Cassia Fistula Extract 250 mg) or 1 Senna Tablet (Senna Extract 250 mg Per Tablet) at bedtime with water for 14 days. All participants then stopped taking the supplements for seven days, then follow up was completed to analyze symptoms.

After 21 days, results showed:

• Significantly reduced straining, increase in bowel satisfaction, and reduction in associated constipation symptoms (headache, abdominal distention, etc) in both groups
• Significant reduction in blockage sensation in the CaFi group indicating its non-habit-forming nature
• Reduced time spent first for defecation after completing the study product in the CaFi group
• Laboratory safety parameters and vitals were within normal range for both groups

In the control group, eight participants reported abdominal discomfort, gripping in abdomen, and sensation of defecation, compared with one participant in the CaFi group. Both study products were deemed to be well tolerated by participants.

The press release also noted that dosages of CaFi are able to be formatted in powders, syrups, tablets, capsules, gummies, and bars.